Project Grant HT94252410799
Award Date 8/15/24
Completion Date 8/14/26
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- This Project Grant award from the Defense Health Agency provides $979,875 to Dana-Farber Cancer Institute, Inc. for research under the Military Medical Research and Development program. The award aims to further optimize dual-targeted CAR T cells to achieve cures for advanced clear cell renal cell carcinoma (CCRCC) by fine-tuning CAR constructs against carbonic anhydrase IX and CD70 antigens based on tumor expression levels. Brigham and Women's Hospital, Inc. will receive a sub-award to...
- The Dana-Farber Cancer Institute, Inc. was awarded a $267,000 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to conduct pre-industrial studies of a first-generation dual-targeted, fine-tuned, immune-restoring chimeric antigen receptor T-cell therapy to achieve cures of clear cell renal cell carcinoma. The two-year award period runs from September 30, 2021 through September 30, 2023 and will support...
- The Project Grant award of $1,387,727.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma" research project conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The award period runs from September 1, 2025 to August 31, 2029. The research aims to advance the scientific understanding and develop innovative diagnostic...
- This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
- The Department of the Army Medical Command awarded a $347,100 project grant to Dana-Farber Cancer Institute, Inc. doing business as Dfci, for the period of March 1, 2022 through February 28, 2025. The grant supports research entitled "Derepression of Human Endogenous Retrovirus and Implications for Immunotherapy for Clear Cell Renal Cell Carcinoma" under the Military Medical Research and Development program. This project will investigate medical solutions for clear cell renal cell...
- This federal Project Grant award of $778,092.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy approach for treating high-grade serous ovarian cancer. The award was made to the Dana-Farber Cancer Institute, Inc. (DFCI), a leading cancer research and treatment center in Boston, MA, on April 15, 2025, with a planned completion date of April 14,...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
- This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
- This Project Grant award in the amount of $322,371.00 from the Defense Health Agency (DHA) was provided to Yale University on May 15, 2024 under the Military Medical Research and Development program (CFDA 12.420). The award supports the research project "OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITOR-BASED THERAPIES FOR RENAL CELL CARCINOMA" with a planned completion date of May 14, 2027. The goal of this grant is to advance scientific understanding and therapeutic approaches for...